Literature DB >> 7706720

Expression of the Fas ligand in cells of T cell lineage.

T Suda1, T Okazaki, Y Naito, T Yokota, N Arai, S Ozaki, K Nakao, S Nagata.   

Abstract

Fas ligand (FasL) is a membrane-type cytokine belonging to the TNF family, and induces apoptosis through its cell-surface receptor, Fas. To determine the cell types that express FasL, various mouse tissues and cell lines were examined by Northern hybridization using a mouse FasL cDNA as a probe. Among tissues, lymphoid organs (thymus, lymph node, spleen), lung, and small intestine express low levels of FasL mRNA, suggesting the role of FasL in the general immune system and mucosal immunity. The testis expressed FasL mRNA most abundantly; however, the size of FasL mRNA in the testis was slightly shorter than those in other tissues. Distribution of FasL mRNA in a panel of cell lines indicated that the FasL expression is rather restricted to the cells of T cell lineage. Activation of the splenocytes with the T cell activators such as PMA and ionomycin, Con A, anti-CD3, or even IL-2 alone induced the expression of the FasL. CD8+ splenocytes expressed the FasL more abundantly than did the CD4+ splenocytes upon activation by Con A and IL-2. Among CD4+ CTL cell lines, the FasL was expressed in all Th1 and Th0, and some Th2 clones.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7706720

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  98 in total

1.  Cytokine production and apoptosis among T cells from patients under treatment for Plasmodium falciparum malaria.

Authors:  K Kemp; B D Akanmori; V Adabayeri; B Q Goka; J A L Kurtzhals; C Behr; L Hviid
Journal:  Clin Exp Immunol       Date:  2002-01       Impact factor: 4.330

Review 2.  Control of death receptor ligand activity by posttranslational modifications.

Authors:  R Weinlich; T Brunner; G P Amarante-Mendes
Journal:  Cell Mol Life Sci       Date:  2010-03-20       Impact factor: 9.261

3.  Cartilage-hair hypoplasia syndrome: increased apoptosis of T lymphocytes is associated with altered expression of Fas (CD95), FasL (CD95L), IAP, Bax, and Bcl2.

Authors:  L Yel; S Aggarwal; S Gupta
Journal:  J Clin Immunol       Date:  1999-11       Impact factor: 8.317

4.  Elevated levels of soluble Fas (APO-1, CD95), soluble Fas ligand, and matrix metalloproteinase-3 in sera from patients with active untreated adult onset Still's disease.

Authors:  Der-Yuan Chen; Joung-Liang Lan; Fang-Ju Lin; Tsu-Yi Hsieh
Journal:  Clin Rheumatol       Date:  2006-09-14       Impact factor: 2.980

Review 5.  Fas (CD95, Apo-1) ligand gene transfer.

Authors:  S E Lamhamedi-Cherradi; Y Chen
Journal:  J Clin Immunol       Date:  2001-01       Impact factor: 8.317

6.  IFN-gamma and Fas/FasL are required for the antitumor and antiangiogenic effects of IL-12/pulse IL-2 therapy.

Authors:  J M Wigginton; E Gruys; L Geiselhart; J Subleski; K L Komschlies; J W Park; T A Wiltrout; K Nagashima; T C Back; R H Wiltrout
Journal:  J Clin Invest       Date:  2001-07       Impact factor: 14.808

7.  End-organ damage in a mouse model of fulminant liver inflammation requires CD4+ T cell production of IFN-gamma but is independent of Fas.

Authors:  Richard T Robinson; Jing Wang; James G Cripps; Michael W Milks; Kathryn A English; Todd A Pearson; James D Gorham
Journal:  J Immunol       Date:  2009-03-01       Impact factor: 5.422

8.  Th1 CD4+ lymphocytes delete activated macrophages through the Fas/APO-1 antigen pathway.

Authors:  D Ashany; X Song; E Lacy; J Nikolic-Zugic; S M Friedman; K B Elkon
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-21       Impact factor: 11.205

9.  Expression of apoptosis-related proteins in rat with induced colitis.

Authors:  Giuseppe D'Argenio; Maria Grazia Farrace; Vittorio Cosenza; Francesca De Ritis; Nicola Della Valle; Francesco Manguso; Mauro Piacentini
Journal:  Int J Colorectal Dis       Date:  2004-04-09       Impact factor: 2.571

10.  Apoptosis of nur77/N10-transgenic thymocytes involves the Fas/Fas ligand pathway.

Authors:  F Weih; R P Ryseck; L Chen; R Bravo
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-28       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.